Filanesib

Myelodysplastic Syndrome

PfizerSmall moleculePhase 1/2Dormant

CCC

52/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 37/ 100
Competitive Position: 95/ 100

Competitive context

296 Active assets in the Myelodysplastic Syndrome cohort.

Asset / Sponsor	Phase	Rating
Cyclophosphamide Sawa Ito, MD	Phase 4	BB
Nivestim City of Hope Medical Center	Phase 4	BB
BUSULFANUM Sawa Ito, MD	Phase 4	BB
Daunomycin OHSU Knight Cancer Institute	Phase 3	BB
Cytarabine The First Affiliated Hospital of Soochow University	Phase 4	BB

View all 50 →

Same molecule, other indications

Filanesib is also rated in:

plasma cell myelomaDormant

BBB

Indicative · Phase 2

76 / 100

plasma cell leukemiaDormant

CCC

Indicative · Phase 1/2

55 / 100

acute myeloid leukemiaDormant

CC

Indicative · Phase 1/2

42 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.